Rhythm Biosciences Limited · ASX:RHY

Rhythm Biosciences — Shareholder Meeting (November 2020)

13 slides from Rhythm Biosciences's shareholder meeting presentation, Nov 18, 2020

  1. Slide 1: AGM Presentation - November 2020

    A transformative, predictive cancer diagnostics technology company Initial Product Aim = ColoSTAT® the early detection of colorectal cancer using a simple, accurate & low-cost blood test, designed for global mass-market screening. AGM Presentation - November 2020 ASX: RHY © Rhythm Biosciences Ltd. A

  2. Slide 2: Important Notice

    Important Notice • This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations o

  3. Slide 3: Corporate Overview

    Corporate Overview Rhythm Biosciences (ASX: RHY) Financial Information ASX Code: RHY A transformative, predictive cancer Share Price (13 November 2020) $0. 375 diagnostics technology company 12-Month Range $0.041 - $0.420 ✓ RHY is a new-generation / disruptive Shares on Issue ~201.496m cancer diagno

  4. Slide 4: Board and Management

    Board and Management A strong and industry experienced board and management team, with a pedigree of building successful businesses. OTTO BUTTULA GLENN GILBERT TREVOR LOCKETT LOU PANACCIO DAVID WHITE EDUARDO VOM Chief Executive Technical – Non-Executive Non-Executive Non-Executive Chairman Officer E

  5. Slide 5: Key Investment Highlights

    Key Investment Highlights As a simple, accurate & low-cost blood test, Rhythm’s ColoSTAT® has potential to substantially increase global mass market screening ✓ Transformative diagnostic company: Focused on early detection of colorectal cancer (CRC) using a simple, low-cost blood test that could rev

  6. Slide 6: Key Investment Highlights

    Key Investment Highlights As a simple, accurate & low-cost blood test, Rhythm’s ColoSTAT® has potential to substantially increase global mass market screening ✓ Sound technology: 13+ years of R&D pioneered by CSIRO^ giving confidence in the biomarkers selected. ✓ Key Lead Biomarker a potential Platf

  7. Slide 7: Key Achievements - Delivered in 2020

    Key Achievements - Delivered in 2020 ✓ Technically validated the key lead and four adjunct biomarkers. ✓ Appointed additional clinical trial (Study 7) sites. ✓ ISO13485 Quality Management System certification maintained. ✓ Completed reagent development program. ✓ Commenced high-volume manufacturer s

  8. Slide 8: Key Achievements - ColoSTAT® Performance

    Key Achievements - ColoSTAT® Performance Prototype test-kit results outperform current global market standard Fung et al. Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One (2015) 10 3. Morikawa et al., Gastroenterology (2005); 129: 422-428 Specificity of 95% is the

  9. Slide 9: Market Opportunity – Global screening numbers

    Market Opportunity – Global screening numbers Screening compliance & opportunity by market Europe (incl UK) China 19 % 38 % 63 50-74 population Japan 38 USA % 396.6M % 50-74 population 231.2M 321.2M 50-74 population unscreened 50-74 population 93.6M 41.5M 143.4M unscreened 34.7M 25.7M unscreened uns

  10. Slide 10: Market Penetration

    Potential ColoSTAT ® Total market Size (50-74yr old only) $4.68bn $11.56bn $336.5m $19.83bn $2.08bn (Patient/market share 50-74-year olds) Market Penetration 75% $3.51bn $8.67bn $252.4m $14.87bn $1.56bn $28.86bn 50% $2.34bn $5.78bn $168.2m $9.91bn $1.04bn $19.24bn 25% $1.17bn $2.89bn $84.13m $4.96bn

  11. Slide 11: IP – Patents filed in all major target markets

    IP – Patents filed in all major target markets ➢ Licensed from CSIRO Granted Pending ➢ Worldwide exclusive licence Australia France Brazil Germany ➢ Patent wholly owned by Vision China (x2) India Tech Bio Pty Ltd* Japan Italy United States ➢ Expires 2031 United Kingdom Luxembourg Netherlands ➢ Metho

  12. Slide 12: Future value inflection points – 2020-2021

    Future value inflection points – 2020-2021 With R&D significantly de-risked, anticipated near-term value inflection points on the path to towards commercialisation include: ➢ Further clinical trial sites to be appointed to accelerate recruitment. ➢ Design transfer of the ColoSTAT® prototype test-kit

  13. Slide 13: Thank you

    Glenn Gilbert CEO, Rhythm Biosciences glenn.gilbert@rhythmbio.com Thank you www.rhythmbio.com © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL 13

Rhythm Biosciences — Shareholder Meeting (November 2020) on 6ix